peptide hormone is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
== Uses == L-citrulline is sold as a dietary supplement. It may be used in commercial products as a topical moisturizing agent for skin or for hairstyling. Although promoted to support athletic performance, there is no good evidence that taking citrulline as a supplement is effective or safe for this purpose. Citrulline has not been approved as a prescription drug, has no confirmed clinical uses, and remains under preliminary research, as of 2026.
Amphetamine has a very similar structure and function to the endogenous trace amines, which are naturally occurring neuromodulator molecules produced in the human body and brain. Among this group, the most closely related compounds are phenethylamine, the parent compound of amphetamine, and N-methylphenethylamine, a structural isomer of amphetamine (i.e., it has an identical molecular formula). In humans, phenethylamine is produced directly from L-phenylalanine by the aromatic amino acid decarboxylase (AADC) enzyme, which converts L-DOPA into dopamine as well. In turn, N-methylphenethylamine is metabolized from phenethylamine by phenylethanolamine N-methyltransferase, the same enzyme that metabolizes norepinephrine into epinephrine. Like amphetamine, both phenethylamine and N-methylphenethylamine regulate monoamine neurotransmission via TAAR1; unlike amphetamine, both of these substances are broken down by monoamine oxidase B, and therefore have a shorter half-life than amphetamine.
p3 peptide is known to have a role in AD and DS, however it has not been clearly determined yet. In order to study the function of p3 peptide in AD, specific antibodies’ location techniques have been used to determine its absence or sparseness in aged non-AD brains. As it turns out, p3 peptide is prevalent in selected areas of AD brain in diffuse deposits and in a subset of dystrophic neuritis, both located in the temporal lobe limbic system. Although p3 peptide can assemble into fibrillar aggregates, its hydrophobic properties make it unable to rest in oligomeric forms. This might explain why p3 has no impact on synaptic function and therefore in AD, since it is a non-amyloidogenic product of APP. Despite this fact, p3 has been proved to have a role in formation of non-fibrillar deposits or lesions associated with DS, another neurological disorder that progresses at a faster rate than AD. Accordingly, DS patients have three copies of the APP gene, as they have three copies of the chromosome 21, so APP is overexpressed in the brain and AD develops at an early age. The disruption of the normal function of APP in AD and, consequently, in DS, including overexpression or altered processes, is the most likely explanation for amyloid plaque formation and subsequent neuronal loss and dementia, associated to memory, spatial disorientation and deterioration of intellectual capacity. Since p3 has not been studied deeply, there are different opinions about its role in brain.
The AAA pathway involves the condensation of α-ketoglutarate and acetyl-CoA via the intermediate AAA for the synthesis of L-lysine. This pathway has been shown to be present in several yeast species, as well as protists and higher fungi. It has also been reported that an alternative variant of the AAA route has been found in Thermus thermophilus and Pyrococcus horikoshii, which could indicate that this pathway is more widely spread in prokaryotes than originally proposed. The first and rate-limiting step in the AAA pathway is the condensation reaction between acetyl-CoA and α‑ketoglutarate catalysed by homocitrate-synthase (HCS) (E.C 2.3.3.14) to give the intermediate homocitryl‑CoA, which is hydrolysed by the same enzyme to produce homocitrate. Homocitrate is enzymatically dehydrated by homoaconitase (HAc) (E.C 4.2.1.36) to yield cis-homoaconitate. HAc then catalyses a second reaction in which cis-homoaconitate undergoes rehydration to produce homoisocitrate. The resulting product undergoes an oxidative decarboxylation by homoisocitrate dehydrogenase (HIDH) (E.C 1.1.1.87) to yield α‑ketoadipate. AAA is then formed via a pyridoxal 5′-phosphate (PLP)-dependent aminotransferase (PLP-AT) (E.C 2.6.1.39), using glutamate as the amino donor. From this point on, the AAA pathway varies with [something is missing here ? -> at the very least, section header! ] on the kingdom.
Sources: en.wikipedia.org
=== Conversion ratio === One measure of a reactor's performance is the "conversion ratio", defined as the ratio of new fissile atoms produced to fissile atoms consumed. All proposed nuclear reactors except specially designed and operated actinide burners experience some degree of conversion. As long as there is any amount of a fertile material within the neutron flux of the reactor, some new fissile material is always created. When the conversion ratio is greater than 1, it is often called the "breeding ratio". For example, commonly used light water reactors have a conversion ratio of approximately 0.6. Pressurized heavy-water reactors running on natural uranium have a conversion ratio of 0.8. In a breeder reactor, the conversion ratio is higher than 1. "Break-even" is achieved when the conversion ratio reaches 1.0 and the reactor produces as much fissile material as it uses.
It is descriptive rather than prescriptive. Bias and unfairness may go undetected because the developers are overwhelmingly white and male: among AI engineers, about 4% are black and 20% are women. There are various conflicting definitions and mathematical models of fairness. These notions depend on ethical assumptions, and are influenced by beliefs about society. One broad category is distributive fairness, which focuses on the outcomes, often identifying groups and seeking to compensate for statistical disparities. Representational fairness tries to ensure that AI systems do not reinforce negative stereotypes or render certain groups invisible. Procedural fairness focuses on the decision process rather than the outcome. The most relevant notions of fairness may depend on the context, notably the type of AI application and the stakeholders. The subjectivity in the notions of bias and fairness makes it difficult for companies to operationalise them. Having access to sensitive attributes such as race or gender is also considered by many AI ethicists to be necessary in order to compensate for biases, but it may conflict with anti-discrimination laws. At the 2022 ACM Conference on Fairness, Accountability, and Transparency a paper reported that a CLIP‑based (Contrastive Language-Image Pre-training) robotic system reproduced harmful gender‑ and race‑linked stereotypes in a simulated manipulation task.
==== Liberation of Czechoslovakia ==== On 8 May 1944, Beneš signed an agreement with Soviet leaders stipulating that "Czechoslovak territory liberated by Soviet armies" would be placed under Czechoslovak civilian control. On 21 September, Czechoslovak troops formed in the Soviet-liberated village, Kalinov, which was the first liberated settlement of Slovakia, located near the Dukla Pass in northeastern part of the country. Slovakia and the Czech lands were occupied mostly by Soviet troops (the Red Army), supported by Czech and Slovak resistance, from the east to the west; only southwestern Bohemia was liberated by other Allied troops from the west. Even at the end of the war, German troops massacred Czech civilians; the Massacre in Trhová Kamenice and the Massacre at Javoříčko are examples of this. A provisional Czechoslovak government was established by the Soviets in the eastern Slovak city of Košice on 4 April 1945. "National committees" (supervised by the Red Army) took over the administration of towns as the Germans were expelled. Bratislava was taken by the Soviets on 4 April. On April 18th, 1945, elements of the U.S. 90th Infantry Division of General George S. Patton’s U.S. 3rd Army crossed the western border of the former Czechoslovakia border near the town of Cheb, effectively cutting Germany in half. Elements of the 3rd Army would probe the Czech border for the rest of April, moving parallel down the border in an advance towards Linz, Austria.
== Applications == In the presence of iron chloride or copper chloride catalyst, or of liquid sulfur at 120 °C Diallyl disulfide can be used as a precursor for the synthesis of higher diallyl polysulfides (polysulfanes). In agriculture, diallyl disulfide and related diallyl polysulfides show useful activity as environmentally-benign nematicides. Diallyl disulfide is also a starting material for the synthesis of allicin. In the food industry, diallyl disulfide is used to improve the taste of meat, vegetables and fruits.
He went on to graduate school at the California Institute of Technology (Caltech) in Pasadena, California, under the guidance of Roscoe Dickinson and Richard Tolman. His graduate research involved the use of X-ray diffraction to determine the structure of crystals. He published seven papers on the crystal structure of minerals while he was at Caltech. He received his PhD in physical chemistry and mathematical physics, summa cum laude, in 1925.
Sources: en.wikipedia.org
== Function == Serpin A12 is a protease inhibitor with an approximate weight of 47 kDa and is a member of the adipokine family of cytokines excreted by adipose tissue. Members of this family regulate a number of cellular processes, such as inflammation mediation and insulin resistance. Made up of 414 amino acids, its main function is modulating the insulin inhibiting protease KLK7, mainly in adipose tissue. Among other functions, Serpin A12 performs insulin-sensitizing actions. Serpin A12 treatment of obese and insulin-resistant mice has been shown to decrease the expression of insulin resistance genes in white adipose tissue as well as improving carbohydrate resistance. Serpin A12 also increases bone density, which helps prevent osteoporosis. It does so by regulating osteoblasts, assisting in their mineralization of the bone matrix, thus balancing bone formation with bone resorption.
Protein C, also known as autoprothrombin IIA and blood coagulation factor XIV, is a zymogen, that is, an inactive enzyme. The activated form plays an important role in regulating anticoagulation, inflammation, and cell death and maintaining the permeability of blood vessel walls in humans and other animals. Activated protein C (APC) performs these operations primarily by proteolytically inactivating proteins Factor Va and Factor VIIIa. APC is classified as a serine protease since it contains a residue of serine in its active site. In humans, protein C is encoded by the PROC gene, which is found on chromosome 2. The zymogenic form of protein C is a vitamin K-dependent glycoprotein that circulates in blood plasma. Its structure is that of a two-chain polypeptide consisting of a light chain and a heavy chain connected by a disulfide bond. The protein C zymogen is activated when it binds to thrombin, another protein heavily involved in coagulation, and protein C's activation is greatly promoted by the presence of thrombomodulin and endothelial protein C receptors (EPCRs). Because of EPCR's role, activated protein C is found primarily near endothelial cells (i.e., those that make up the walls of blood vessels), and it is these cells and leukocytes (white blood cells) that APC affects. Because of the crucial role that protein C plays as an anticoagulant, those with deficiencies in protein C, or some kind of resistance to APC, suffer from a significantly increased risk of forming dangerous blood clots (thrombosis).
=== Overnutrition === Excessive consumption of energy-dense foods and drinks and limited physical activity causes overnutrition. It causes overweight, defined as a body mass index (BMI) of 25 or more, and can lead to obesity (a BMI of 30 or more). Obesity has become a major health issue worldwide. Overnutrition is linked to chronic non-communicable diseases like diabetes, certain cancers, and cardiovascular diseases. Hence identifying and addressing the immediate risk factors has become a major health priority. The recent evidence on the impact of diet-induced obesity in fathers and mothers around the time of conception is identified to negatively program the health outcomes of multiple generations. According to UNICEF, at least 1 in every 10 children under five is overweight in 33 countries.
Since the twenty newly created districts differed geographically from the twelve older ones, the original parish registers up to 1792 and civil records covering 1793 to 1859 were stored at City Hall, along with those of fully annexed communes. All duplicates, forming the "Greffe collection," were stored at the Palais de Justice. Partially annexed communes retained their original registers, but their duplicates were also sent to the Palais de Justice.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.